SM
MRTX

Sabby Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Sabby Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5,000
Closed -$776K – 221
2021
Q3 		$885K Sell
5,000
-1,000
-17% -$161K 0.12% 91
2021
Q2 		$969K Sell
6,000
-2,500
-29% -$401K 0.14% 83
2021
Q1 		$1.46M Buy
8,500
+5,500
+183% +$1.09M 0.28% 66
2020
Q4 		$659K Buy
+3,000
New +$649K 0.13% 58
2017
Q3 		– Sell
-255,100
Closed -$921K – 219
2017
Q2 		$921K Buy
255,100
+5,365
+2% +$20.6K 0.06% 108
2017
Q1 		$1.3M Buy
249,735
+150,000
+150% +$822K 0.07% 117
2016
Q4 		$474K Hold
99,735
– – 0.03% 199
2016
Q3 		$659K Sell
99,735
-7,500
-7% -$39.9K 0.02% 212
2016
Q2 		$586K Buy
107,235
+50,835
+90% +$810K 0.03% 204
2016
Q1 		$1.21M Buy
56,400
+30,373
+117% +$679K 0.06% 142
2015
Q4 		$822K Sell
26,027
-33,973
-57% -$1.2M 0.05% 206
2015
Q3 		$2.06M Buy
+60,000
New +$1.81M 0.09% 151
2014
Q1 		– Sell
-12,213
Closed -$203K – 277
2013
Q4 		$203K Buy
+12,213
New +$209K 0.01% 184

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Sabby Management's MRTX Position: Q4 2021 in Review

Sabby Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2021, closing a stake of 5,000 shares — an estimated $776K sold.

Sabby Management first reported a position in MRTX in Q4 2013 and held it in 13 quarters. The position peaked at $2.06M in Q3 2015. 260 funds tracked by Wall St. Rank hold MRTX as of Q4 2021.

  • Sabby Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Sabby Management sold 5,000 Mirati Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $776K.
  • Sabby Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2013 and held it in 13 quarters.
  • Sabby Management's Mirati Therapeutics, Inc. Common Stock position peaked at $2.06M in Q3 2015.
  • 260 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Sabby Management's 13F filing for Q4 2021, filed 14 Feb 2022.